Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Urology 1/2015

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer

Zeitschrift:
BMC Urology > Ausgabe 1/2015
Autoren:
Jae Young Joung, Jeong Eun Kim, Sung Han Kim, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JYJ designed the study and wrote the manuscript. SHK participated in the study design. JEK helped to draft the manuscript. SHK did statistical analysis for the clinical factors of the patients. JEK managed and analyzed the raw data of the characteristics of the patients. WSP helped to design the study and draft the manuscript. JYJ and HKS analyzed the reference data. KHL and JC designed and supervised the study. JEK and EKH reviewed the previous data. All authors read and approved the final manuscript.

Abstract

Background

To identify the prevalence and clinical outcomes of pT0 disease following neoadjuvant hormonal therapy (NHT) and radical prostatectomy (RP) in high-risk prostate cancer.

Methods

We retrospectively included 111 patients who had received NHT and RP for the treatment of high-risk prostate cancer. We classified the patients into two groups, the pT0 group and the non-pT0 group, depending on whether a residual tumor was observed.

Results

We identified 6 cases (5.4 %) with pT0 disease after reviewing the slides of all patients. There was no recurrence of disease in the pT0 group during a median follow-up of 59 months. Among the 105 patients in the non-pT0 group, biochemical recurrence (BCR) developed in 60 patients (57.1 %), with the median time to BCR being 14 months.

Conclusions

Among the 111 patients with high-risk prostate cancer, we found 6 cases that showed a complete pathological response after NHT and no recurrence of disease during the follow-up, meaning that the androgen deprivation therapy could potentially eradicate high-risk prostate cancer. This is one of the largest studies demonstrating the prevalence of pT0 disease and its outcomes after NHT among patients with high-risk prostate cancer.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Urology 1/2015 Zur Ausgabe

Neu im Fachgebiet Urologie

Meistgelesene Bücher in der Urologie

2016 | Buch

Anogenitale Hautkrankheiten

Erkennen, Befunden, Behandeln

Hautkrankheiten im Bereich Genitale werden werden oft erstmals von einem Facharzt beobachtet, der sich mit anderen genitalen Beschwerden beschäftigt – der Urologe bei Männern oder der Gynäkologe bei Frauen. Dieses Buch schult den Blick für anogenitale Dermatosen und gibt Tipps zur Therapie.

Herausgeber:
Walter Krause, Isaak Effendy

2015 | Buch

Inkontinenz- und Deszensuschirurgie der Frau

Harninkontinenz ist eines der häufigsten Symptome in der Urologie und Gynäkologie. OP-Atlas, unverzichtbarer Ratgeber, kompaktes Nachschlagewerk in einem: Mithilfe dieses Buches werden Sie Spezialist in Sachen Inkontinenz- und Deszensuschirurgie.

Herausgeber:
Rainer Hofmann, Uwe Wagner

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise